2 growth champions I’d buy and hold for two decades

These companies have room to expand rapidly over the next 20 years.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

In my opinion, the best companies to hold for the long term are those with a long runway for growth. Companies which have an enormous market to expand into are more likely to be able to continue to grow, especially when government-sponsored initiatives are providing a tailwind. 

Indivior (LSE: INDV) and Harworth Group (LSE: HWG) are excellent examples. Indivior delivers treatments to help overcome opioid addiction, a severe problem the United States is currently facing, with speculation it could be the largest health crisis the country has ever seen. 

Meanwhile, Harworth is working to become a major home builder in the United Kingdom. Both of these markets are huge and have political backing.

Policy makers in the US are beginning to take action on the opioid crisis, while UK policymakers are encouraging homebuilders to accelerate construction and meet rising housing demand.

Building for Britain 

Harworth announced today that, as a continuation of its strategy to generate the most value for shoulders, it has acquired “four strategic sites across the North of England and the Midlands, for a total consideration of £45m plus acquisition costs.” These sites include three separate parcels near Denby in Derbyshire with the potential to build up to 3,000 new homes and 450,000 sq ft of commercial space. 

As Harworth continues to build its presence in the housing market, I believe the company could generate tremendous returns for investors, especially as the government continues to devote money in time to helping developers build new homes. 

And right now, shares in the business look cheap, trading at a price to book value of only 0.9. According to the last set of available figures, the book value per share is 129p, indicating an upside of 14% as the company continues to grow. At present, the shares only support a dividend yield of 0.8%, although I expect this to rise steadily in the years ahead as Harworth’s current building plan gets underway. 

Fighting addiction 

Today’s figures from Indivior, for the first three months of the year, are disappointing. But it’s the company’s future of potential I’m excited about. 

Excluding the impact of one-off items, net income declined 3% to $78m in Q1 as revenue fell 6%, thanks mainly due to competition. However, this year the company is introducing its new Sublocade opioid treatment to the market. Launched during the first week of February, initial indications show that this treatment could be a “transformational tool in the fight against the opioid epidemic“, according to Indivior CEO Shaun Thaxter. 

The introduction of this product is expected to lessen the group’s reliance on sales of legacy products, which are coming under attack from generic competitors. And even though earnings are expected to decline over the next two years, as Sublocade sales gain traction and more money is devoted to fighting the opioid epidemic, I believe Indivior’s earnings weakness should not last. 

It may take some time, but I think that this is one company worth watching over the next decade as the war against opiate addiction gains traction. There’s also the possibility Indivior will succumb to a takeover if a larger peer wants to get its hands on the firm’s intellectual property

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns no share mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »